Back
Bertoni_2022_Wiley_bjhaem
Journal article

United we stand : double targeting of CD79B and CD20 in diffuse large B-cell lymphoma

  • Tarantelli, Chiara ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Bertoni, Francesco ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • 2022
Published in:
  • British Journal of Haematology. - 2022, vol. 199, p. 169–170
Antibody-drug conjugate
Lymphoma
MMAE
Polatuzumab vedotin
Resistance
Rituximab
English Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.
Collections
Language
  • English
Classification
Medicine
License
CC BY-NC-ND
Open access status
hybrid
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1322803
Statistics
Document views: 28 File downloads:
  • Bertoni_2022_Wiley_bjhaem.pdf: 134